UniLife Corporation
(ASX:UNS) (NASDAQ:UNIS) has signed a 10 year commercial supply agreement with a global pharmaceutical company for the use of its Depot-ject delivery system for ocular injection therapy.
The customer and its therapy are subject to confidentiality clauses but Unilife anticipates a maximum two year period for customization and regulatory approval before the therapy will be commercially available.
Unilife has agreed to exclusive access to its patented delivery system for this particular therapeutic area. Depot-ject allows clinicians to precisely implant therapy directly into a targeted area of the eye.
Unilife reported a net loss of $61.4 million for the 2014 financial year.
